[go: up one dir, main page]

KR970705401A - HYALURONIC ACID AND DERIVATIVES FOR MODULATION OF CELLULAR ACTIVITY FOR ADJUSTING CELL ACTIVITY - Google Patents

HYALURONIC ACID AND DERIVATIVES FOR MODULATION OF CELLULAR ACTIVITY FOR ADJUSTING CELL ACTIVITY

Info

Publication number
KR970705401A
KR970705401A KR1019970701164A KR19970701164A KR970705401A KR 970705401 A KR970705401 A KR 970705401A KR 1019970701164 A KR1019970701164 A KR 1019970701164A KR 19970701164 A KR19970701164 A KR 19970701164A KR 970705401 A KR970705401 A KR 970705401A
Authority
KR
South Korea
Prior art keywords
hyaluronic acid
acid type
daltons
disease
cell surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019970701164A
Other languages
Korean (ko)
Inventor
사무엘 시몬 에스큘라이
Original Assignee
사무엘 시몬 에스큘라이
하알 팔마큐티칼 코오퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002131130A external-priority patent/CA2131130A1/en
Priority claimed from CA 2145605 external-priority patent/CA2145605A1/en
Application filed by 사무엘 시몬 에스큘라이, 하알 팔마큐티칼 코오퍼레이션 filed Critical 사무엘 시몬 에스큘라이
Publication of KR970705401A publication Critical patent/KR970705401A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

사람에서 히알루론산의 높은 친화성 세포 표면 수용체를 발현하는 조직과 세포 예로써 흡착 분자(ICAM-1, HARLEC 그리고 CD44)와 조절분자 (예로써 RHAMM)의 세포활성을 조절하는 방법에 있어서, 그 방법은 히알루론산형 (예로써, 히알루론산, 이의 제약학적으로 수용 가능한 염 예로써, 분자량이 750,000달톤이하 예로써, 225,000달톤을 가지는 히알루론산염 그리고 150,000-225,000범위내에 Hyal Pharmaceutical Corporation에서 그리고 U.S. 특허 출원 08/143,983에서 상술된 것과 히알루론산염 형의 분자량 분설(50,000-100,000달톤, 250,000- 내지 350,000달톤 그리고 500,000-730,000달톤에서의 것과 같은 캐나다 특허 1205031(Fidia)에서 상술된 분설] 또는 동사체, 유사체, 유도체, 복합체, 에스테르, 히알루론산의 분설 또는 서브유닛 또는 이의 복합체 히알루론산형의 동일한 세포 표면 수용체에 결합할 수 있는 능력에 대해 히알루론산형을 모방하는 분자의 효과량을 투여하여 인체에서 히알루론산형의 높은 친화성 세포 표면 수용체와 같은 분자 예로써 흡착 분자 또는 조절 분자를 발현하는 조직 또는 세포의 세포활성을 조절하게 하여 사람에게서 질병 또는 질환을 예방하게 한다. HA 그리고/또는 HA 모방 분자의 투여는 적절하게는 제약학적 내성이 있는 부형제(예로써, 멸균수)에서 실시한다.(ICAM-1, HARLEC and CD44) and a regulatory molecule (for example, RHAMM) as a cell and tissue that express a highly affinity cell surface receptor of hyaluronic acid in a human, As a hyaluronic acid type (e.g., hyaluronic acid, a pharmaceutically acceptable salt thereof, a hyaluronate having a molecular weight of 750,000 daltons or less, a hyaluronate having a molecular weight of 225,000 daltons, and a Hyal Pharmaceutical Corporation in the range of 150,000-225,000) 08 / 143,983 and molecular weight distributions of the hyaluronic acid type (such as those described in Canadian patent 1205031 (Fidia) such as at 50,000-100,000 daltons, 250,000-350,000 daltons and 500,000-730,000 daltons) , Derivatives, complexes, esters, hyaluronic acid, or complexes thereof, or hyaluronic acid type An effective amount of a molecule that mimics a hyaluronic acid type is administered to the ability to combine to form a hyaluronic acid type high affinity cell surface receptor in the human body. The HA and / or HA mimetic molecules are suitably administered in a pharmaceutical resistant excipient (e.g., sterile water).

Description

세포활성의 조정용 히알루론산과 그 유도체(HYALURONIC ACID AND DERIVATIVES FOR MODULATION OF CELLULAR ACTIVITY)HYALURONIC ACID AND DERIVATIVES FOR MODULATION OF CELLULAR ACTIVITY FOR ADJUSTING CELL ACTIVITY

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.

Claims (18)

히알루론산의 높은 친화성 세포 표면 수용체를 발현하는 조직과 세포 예로써 흡착 분자(ICAM-1, HARLEC 그리고 CD44) 그리고 /또는 조절 분자 (예로써 RHAMM의 세포활성을 조절하는 방법에 있어서, 이 방법은 히알루론산형(예로써, 히알루론산,이의 제약학적으로 수용 사능한 염[예로써, 분자량이 750,000달톤이한 예로써, 225,000달톤을 가지는] 히알루론산염과 동사체, 유사체, 유도체, 복합체, 에스테르, 히알루론산의 분설 또는 서브유닛 또는 이의 복합체)그리고/또는 히알루론산형의 동일한 세포 표면 수용체에 결합할 수 있는 능력에 대해 히알루론산형을 모방하는 분자의 효과량을 사람에서 내성이 있는 제약학적 부형제와 함께 투여하는 인체에서 히알루론산형의 높은 친화성 세포 표면 수용체를 발현하는 분자 예로써 흡착 분자를 발현하는 조직 또는 세포의 세포활성을 조절하게 하는 것으로 구성된 것을 특징으로 하는 방법.High Affinity of Hyaluronic Acid As tissue and tissues that express cell surface receptors and methods of modulating the cellular activity of adsorbing molecules (ICAM-1, HARLEC and CD44) and / or regulatory molecules (e.g., RHAMM, Analogs, derivatives, complexes, esters and the like of hyaluronic acid type (e.g., hyaluronic acid, its pharmaceutically acceptable salt [for example, hyaluronate having a molecular weight of 750,000 daltons, , A subunit of hyaluronic acid or a subunit or complex thereof) and / or the ability to bind to the same cell surface receptor of hyaluronic acid type, is administered to a human with an effective amount of a pharmaceutical excipient resistant to human hyaluronic acid A molecule that expresses a high affinity cell surface receptor of hyaluronic acid type in a human body to be administered together with a cell or a cell Method that consists in that control the cellular activity which is characterized. 제1항에 있어서, 질병 또는 질환의 치료용 약물 또는 치료요법제를 비-독성효과량으로 구성된 것을 특징으로 하는방법.2. The method of claim 1, wherein the medicament or therapeutic agent for treating a disease or disorder is comprised of a non-toxic effective amount. 제2항에 있어서, 약물 또는 치료요법제는 자유 라디칼 소거제(예로써, 아스코르브산(비타민C), 항암제, 화학요법제, 항-바이러스제 예로써, 비이온성 계면 활성제 예로써, 피임용 크림 DelfenTM에서 볼 수 있는 넌옥시놀-9[넌일페녹시 폴리에틸 에탄올], 그리고 양이온 계면활성제(예로써, 세틸 피리디미늄 클로라이드) 그리고 음이온 계면활성제(예로써, 벤잘코니움 클로라이드)와 같은 항-바이러스제, 비-스테로이드성 항염증제(NSAID) 예로써, 인도메타신, 나프록신, 디클로페낙 그리고 케토로락의 (+/-)트로페타민염(ToadolTM으로 시판됨) 그리고 스테로이드성 항염증 약물, 항-곰팡이제, 해독제(예로써 관장 시에 직장으로 투여되는),진통제, 기관지 확장제, 항-박테리아제, 항생제, 맥과허혈치료용 약물(예로써 당뇨병 그리고 Berger's 질병), 항-신체 단클론제, 모발 성장용 국소 이용용 미녹시돌, 이뇨제(예로써, 퓨로세미드(LasixTM로 시판됨), 면역억제제(예로써 사이클로스포린), 임포킨(인터루킨-2 그리고 그 유사체), 알파-와 베타-인터페론 그리고 그 유사체로 구성된 것을 특징으로 하는 방법.The pharmaceutical composition according to claim 2, wherein the drug or therapeutic agent is selected from the group consisting of free radical scavengers (for example, ascorbic acid (vitamin C), anticancer agents, chemotherapeutic agents, anti-viral agents, examples of nonionic surfactants, Such as nonoxynol-9 [anynyl phenoxypolyethyl ethanol], which can be found in the TM , and cationic surfactants (such as cetylpyridinium chloride) and anionic surfactants (such as benzalkonium chloride) Viral, non-steroidal anti-inflammatory drugs (NSAIDs) Examples of indomethacin, naproxin, diclofenac and ketorolac (+/-) tropetaine salts (marketed as Toadol TM ) and steroidal anti- Antibiotics, drugs for treating vascular and ischemic diseases (such as diabetes and Berger's disease), anti-body monoclonal agents, antimicrobial agents, antimicrobial agents, As to growth topical yiyongyong minok when stone, for diuretic (e.g., furosemide (sold as Lasix TM), immunosuppressive agents (cyclosporin, for example), being pokin (IL-2, and analogues thereof), alpha-and beta-interferon And an analog thereof. 인체에서 히알루론산 형에 대한 높은 친화성 세포 표면 수용체를 발현하는 조직과 세포의 세포 활성을 조절하기 위한 히알루론산형으로써 히알루론산 예로써, 이의 제약학적으로 수용 가능한 염(예로써, 분자량이 750,000달톤이하 예로써, 225,000달톤을 가지는] 히알루론산염과 동사체, 유사체, 유도체, 복합체, 에스테르, 히알루론산의 분설 또는 서브유닛 또는 이의 복합체 그리고/또는 히알루론산형의 동일한 세포 표면 수용체에 결합할 수 있는 능력에 대해 히알루론산형을 모방하는 분자의 용도.High affinity for hyaluronic acid type in human body Hyaluronic acid type for regulating cellular activity of tissues and cells expressing cell surface receptors, such as hyaluronic acid, its pharmaceutically acceptable salts (for example, having a molecular weight of 750,000 daltons As well as hyaluronates, which have a molecular weight of less than or equal to 500,000 daltons and have 225,000 daltons, and which are capable of binding to the same cell surface receptors of hyaluronic acid type and / or complexes, analogs, derivatives, complexes, esters, The use of molecules to mimic the hyaluronic acid form of ability. 제4항에 있어서, 비독성 효과량의 약물이 추가로 구성된 것을 특징으로 하는 용도.5. Use according to claim 4, characterized in that a non-toxic effective amount of the drug is further constituted. 제5항에 있어서, 약물은 예로써, 자유 라디칼 소거제(예로써, 아스코르브산(비타민C), 항암제, 화학요법제, 항-바이러스제 예로써, 비이온성 계면 활성제 예로써, 피임용 크림 DelfenTM에서 볼 수 있는 넌옥시놀-9[넌일페녹시 폴리에틸 에탄올], 그리고 양이온 계면활성제(예로써, 세틸 피리디미늄 클로라이드) 그리고 음이온 계면활성제(예로써, 벤잘코니움 클로라이드)와 같은 항-바이러스제, 비-스테로이드성 항염증제(NSAID) 예로써, 인도메타신, 나프록신, 디클로페낙 그리고 케토로락의 (+/-)트로페타민염(ToadolTM으로 시판됨) 그리고 스테로이드성 항염증 약물, 항-곰팡이제, 해독제(예로써 관장시에 직장으로 투여되는), 진통제, 기관지 확장제, 항 박테리아제, 항생제 맥관허혈치료용 약물(예로써 당뇨병 그리고 Berger's 질병), 항-신체 단클론제, 모발 성장용 국소 이용용 미녹시돌, 이뇨제(예로써, 퓨로세미드(LasixTM로 시판됨), 면역억제제(예로써 사이클로스포린), 임포킨(인터루킨-2 그리고 그 유사체), 알파-와 베타-인터페론 그리고 그 유사체로 구성된 것을 특징으로 하는 용도.The method of claim 5 wherein the drug is for example, free radical scavengers (such as ascorbic acid (vitamin C), anticancer drugs, chemotherapeutic drugs, anti-by-viral agents for example, as a non-ionic surfactant for example, blood delegation cream Delfen TM Anti-viral agents such as nonoxynol-9 [anynyl phenoxypolyethyl ethanol], which are found in US Pat. Non-steroidal anti-inflammatory drugs (NSAIDs) Examples of indomethacin, naproxin, diclofenac and ketorolac (+/-) tropetaine salts (sold as Toadol TM ) and steroidal anti- (Eg diabetes and Berger's disease), anti-body monoclonal agents, hair growth inhibitors, antimicrobial agents, antimicrobial agents, antimicrobial agents, Topical yiyongyong minok when stone, diuretics (such as, furosemide (sold as Lasix TM), immunosuppressive agents (cyclosporin, for example), being pokin (IL-2, and analogues thereof), alpha-and beta-interferons and its analogs ≪ / RTI > 질병 또는 질환을 예방하기 위한 방법에 있어서, 그 방법은 인체에서 히알루론산 형에 대한 높은 친화성 세포 표면 수용체를 발현하는 조직과 세포의 세포 활성을 조절하기 위한 히알루론산형으로써 히알루론산 예로써, 이의 제약학적으로 수용 가능한 염(예로써, 분자량이 750,000달톤이하 예로써, 225,000달톤을 가지는) 히알루론산염과 동사체, 유사체, 유도체, 복합체, 에스테르, 히알루론산의 분설 또는 서브유닛 또는 이의 복합체 그리고/또는 히알루론산형의 동일한 세포 표면 수용체에 결합할 수 있는 능력에 대해 히알루론산형을 모방하는 분자의 효과량을 투여하는 질병 또는 질환을 예방한는 것을 특징으로 하는 방법.A method for preventing disease or disease, the method comprising the steps of: administering to the human body a high affinity hyaluronic acid type hyaluronic acid type for regulating cellular activity of cells and tissues expressing cell surface receptors, such as hyaluronic acid, Analogs, derivatives, complexes, esters, hyaluronic acid derivatives or subunits or complexes thereof and / or complexes of the hyaluronate with a pharmaceutically acceptable salt (e.g. having a molecular weight of less than 750,000 daltons and having a molecular weight of 225,000 daltons) Or an effective amount of a molecule that mimics the hyaluronic acid form for its ability to bind to the same cell surface receptor of the hyaluronic acid type. 제7항에 있어서, 히알루론산형의 투여와 함께 질병 또는 질환을 예방하는 것을 돕는 약물로 구성된 것을 특징으로 하는 방법.8. A method according to claim 7, characterized in that it comprises a drug which aids in the prevention of the disease or disorder together with the administration of the hyaluronic acid type. 사람의 히알루론산형에 대한 높은 친화성 세포 표면 수용체를 발현하는 조직과 세포 (예로써 흡착 분자ICAM-1, HARLEC, CD44 그리고 RHAMM의 세포활성을 조절하기 위해 제공되는 제약학적 조성물의 약량에 있어서, 약량은 알루론산형 (예로써, 히알루론산,이의 제약학적으로 수용 사능한 염 [예로써, 분자량이 750,000달톤이한 예로써, 225,000달톤을 가지는] 히알루론산염과 동사체, 유사체, 유도체, 복합체, 에스테르, 히알루론산의 분설 또는 서브유닛 또는 이의 복합체 히알루론산형의 동일한 세포 표면 수용체에 결합할 수 있는 능력에 대해 히알루론산형을 모방하는 분자의 비-독성 효과량과 제약학적 부형제 (예로써 멸균수)로 구성되는 것을 특징으로 하는 약량.High affinity for human hyaluronic acid type In the amounts of pharmaceutical compositions provided to regulate the cellular activity of tissues and cells expressing cell surface receptors (e.g., adsorption molecules ICAM-1, HARLEC, CD44 and RHAMM, The dosage may be in the form of an alunonic acid type (e.g., hyaluronic acid, a pharmaceutically acceptable salt thereof (e.g., having a molecular weight of 750,000 daltons, having 225,000 daltons) and a conjugate, analogue, Toxic effect of a molecule that mimics the hyaluronic acid form versus the ability to bind to the same cell surface receptors of the hyaluronic acid type of the compound or its complex hyaluronic acid type, and the pharmaceutical excipient (e. G., Sterile ≪ / RTI > number). 제9항에 있어서, 히알루론산을 수반하는 질병 또는 질환을 치료하는 약물 또는 요법제의 비-독성 효과량으로 구성된 것을 특징으로 하는 약량.10. A dosage form according to claim 9, comprising a non-toxic effective amount of a drug or therapeutic agent for treating a disease or condition associated with hyaluronic acid. 제약학적 조성물에 있어서, ⅰ)질병 또는 질환을 치료하기 위해 비-독성 효과량으로 약물 또는 치료제; ⅱ)비-독성 효과량의 히알루론산 형(예로써, 히알루론산,이의 제약학적으로 수용 사능한 염 [예로써, 분자량이 750,000달톤이한 예로써, 225,000달톤을 가지는 히알루론산염] 히알루론산 나트륨의 분자량 분설 그리고 동사체, 유사체, 유도체, 복합체, 에스테르, 히알루론산의 분설 또는 서브유닛 또는 이의 복합체) 그리고 인체에서 히알루론산형의 세포 표면 수용체에 결합할 수 있는 능력에 대해 히알루론산형을 모방하는 분자로써 인체에서 히알루론산형의 높은 친화성 세포 표면 수용체를 발현하는 조직 또는 세포의 세포 활성을 조절하게 하고, 그리고 ⅲ)제약학적 내성이 있는 부형제(예로써, 멸균수); 이때, 성분 (ⅱ)은 제약학적 조성물의 약량이 투여될 때 성분 (ⅱ)은 사람에서 HA 그리고/또는 HA 모방 분자의 수용체에 결합함으로써 사람의 히알루론산 형의 높은 친화성 세포표면 수용체를 발현하는 세포 또는 조직(예로써, ICAM-1, HARLEC, CD44 그리고RHAMM)의 세포 활성을 조절하는 데 이용될 수 있고, 그리고 성분(ⅱ)은 성분(ⅱ)가 히알루론산 형의 경우에 신체 또는 피부로 성분(ⅰ)을 수송하는데 즉시 이용될 수 있는 형으로 구성된 것을 특징으로 하는 제약학적 조성물 약량.A pharmaceutical composition comprising: i) a drug or therapeutic agent in a non-toxic effective amount to treat a disease or disorder; Ii) a non-toxic effective amount of hyaluronic acid type (e.g., hyaluronic acid, a pharmaceutically acceptable salt thereof (e.g., a hyaluronate having a molecular weight of 750,000 daltons and having a molecular weight of 225,000 daltons) sodium hyaluronate Analogs, derivatives, complexes, esters, subunits or subunits of hyaluronic acid or complexes thereof), and the ability to bind hyaluronic acid type cell surface receptors in the human body to mimic the hyaluronic acid type As a molecule, to regulate the cellular activity of tissues or cells expressing high affinity cell surface receptors of the hyaluronic acid type in the human body, and iii) a pharmaceutical resistant excipient (e.g., sterile water); Here, component (ii) is a compound that when administered at a dosage of a pharmaceutical composition, component (ii) binds to a receptor of HA and / or HA mimic molecule in a human, thereby expressing a highly affinity cell surface receptor of human hyaluronic acid type (Ii) can be used to control the cellular activity of cells or tissues (e.g. ICAM-1, HARLEC, CD44 and RHAMM) and component (ii) Wherein the pharmaceutical composition is comprised of a form that is readily available for delivery of component (i). 제11항에 있어서, 적절한 약물과 요법제는 예로써, 자유 라디칼 소거제(예로써, 아스코르브산(비타민C), 항암제, 화학요법제, 항-바이러스제 예로써, 비이온성 계면 활성제 예로써, 피임용 크림 DelfenTM에서 볼 수 있는 넌옥시놀-9[넌일페녹시 폴리에틸 에탄올], 그리고 양이온 계면활성제 (예로써, 세틸 피리디미늄 클로라이드) 그리고 음이온 계면활성제 (예로써, 벤잘코니움 클로라이드)와 같은 항-바이러스제, 비-스테로이드성 항염증제(NSAID) 예로써, 인도메타신, 나프록신, 디클로페낙 그리고 케토로락의 (+/-)트로페타민염(ToadolTM으로 시판됨) 그리고 스테로이드성 항염증 약물, 항-곰팡이제, 해독제(예로써 관장시에 직장으로 투여되는 )진통제, 기관지 확장제, 항-박테리아제, 항생제, 맥관허혈치료용 약물(예로써 당뇨병 그리고 Berger's 질병), 항-신체 단클론제, 모발 성장용 국소 이용용 미녹시돌, 이뇨제(예로써, 퓨로세미드(LasixTM로 시판됨), 면역억제제(예로써 사이클로스포린), 임포킨(인터루킨-2 그리고 그 유사체), 알파-와 베타-인터페론 그리고 그 유사체로 구성된 것을 특징으로 하는 약량.12. The method of claim 11, wherein the appropriate drug and therapeutic agent is selected from the group consisting of, for example, free radical scavengers (e.g., ascorbic acid (vitamin C), anticancer agents, chemotherapeutic agents, anti- (Nonylphenoxypolyethyl ethanol), a cationic surfactant (for example, cetylpyridinium chloride) and an anionic surfactant (for example, benzalkonium chloride), which are found in Delfen TM , (+/-) tropetaine salts of indomethacin, naproxin, diclofenac and ketorolac (commercially available as Toadol TM ) and steroidal anti-inflammatory drugs (NSAIDs) Antibiotics, drugs for treating vasoactive ischemia (such as diabetes and Berger's disease), anti-inflammatory drugs, anti-inflammatory drugs, anti-inflammatory drugs, anti-fungal agents, antidotes (for example, The clone, as when a stone, a diuretic (for example, topical yiyongyong minok for hair growth, furo search three-carboxamide (commercially available as Lasix TM), immunosuppressive agents (cyclosporin, for example), being pokin (IL-2, and analogues thereof), alpha-and Beta-interferon and analogs thereof. 제9,10,11 또는 12항에 따른 약량을 다량 포함하는 용기에 있어서, 이때 개별적인 1회 약량을 용기로부터 취할 수 있는 것을 특징으로 하는 용기.11. A container comprising a large amount of a dosage according to any one of claims 9,10, 11 or 12, wherein a separate, single dose can be taken from the container. ⅰ)질병 또는 질환을 치료하기 위해 비-독성 효과량으로 약물 또는 치료제; ⅱ)비-독성 효과량의 히알루론산 형(예로써, 히알루론산,이의 제약학적으로 수용 사능한 염 [예로써, 분자량이 750,000달톤이한 예로써, 225,000달톤을 가지는 히알루론산염] 히알루론산 나트륨의 분자량 분설 그리고 동사체, 유사체, 유도체, 복합체, 에스테르, 히알루론산의 분설 또는 서브유닛 또는 이의 복합체) 그리고 인체에서 히알루론산형의 세포 표면 수용체에 결합할 수 있는 능력에 대해 히알루론산형을 모방하는 분자로써 인체에서 히알루론산형의 높은 친화성 세포 표면 수용체를 발현하는 조직 또는 세포의 세포 활성을 조절하게 하고, 그리고 ⅲ)제약학적 내성이 있는 부형제(예로써, 멸균수); 이때, 성분 (ⅱ)은 제약학적 조성물의 약량이 투여될 때 성분 (ⅱ)은 사람에서 HA 그리고/또는 HA 모방 분자의 수용체에 결합함으로써 사람의 히알루론산 형의 높은 친화성 세포표면 수용체를 발현하는 세포 또는 조직(예로써, ICAM-1, HARLEC, CD44 그리고RHAMM)의 세포 활성을 조절하는 데 이용될 수 있고, 그리고 성분(ⅱ)은 성분(ⅱ)가 히알루론산 형의 경우에 신체 또는 피부로 성분(ⅰ)을 수송하는데 즉시 이용될 수 있는 형으로 구성된 것을 특징으로 하는 용도.I) a drug or therapeutic agent in a non-toxic effective amount to treat a disease or disorder; Ii) a non-toxic effective amount of hyaluronic acid type (e.g., hyaluronic acid, a pharmaceutically acceptable salt thereof (e.g., a hyaluronate having a molecular weight of 750,000 daltons and having a molecular weight of 225,000 daltons) sodium hyaluronate Analogs, derivatives, complexes, esters, subunits or subunits of hyaluronic acid or complexes thereof), and the ability to bind hyaluronic acid type cell surface receptors in the human body to mimic the hyaluronic acid type As a molecule, to regulate the cellular activity of tissues or cells expressing high affinity cell surface receptors of the hyaluronic acid type in the human body, and iii) a pharmaceutical resistant excipient (e.g., sterile water); Here, component (ii) is a compound that when administered at a dosage of a pharmaceutical composition, component (ii) binds to a receptor of HA and / or HA mimic molecule in a human, thereby expressing a highly affinity cell surface receptor of human hyaluronic acid type (Ii) can be used to control the cellular activity of cells or tissues (e.g. ICAM-1, HARLEC, CD44 and RHAMM) and component (ii) Lt; RTI ID = 0.0 > (i). ≪ / RTI > 제14항에 있어서, ⅰ) 감기; ⅱ) 발작; ⅲ)염증 과정; ⅳ) 섬유증 그리고 ⅴ) 암 제어에서 선택된 질병 또는 질환의 치료 또는 예방이 필요한 경우에 예방 또는 치료를 위해 조직과 세포의 세포활성을 조절하는 것을 특징으로 하는 용도.15. The method of claim 14, further comprising: i) winding; Ii) seizures; Iii) inflammatory processes; Fibrosis, and v) controlling the cellular activity of tissues and cells for prophylaxis or treatment when treatment or prevention of a disease or disorder selected in cancer control is required. 제1항또는 2항에 있어서, ⅰ) 감기; ⅱ) 발작; ⅲ)염증 과정; ⅳ) 섬유증 그리고 ⅴ) 암 제어에서 선택된 질병 또는 질환의 치료 또는 예방이 필요한 경우에 예방 또는 치료를 위해 조직과 세포의 세포활성을 조절하는 것을 특징으로 하는 방법.The method according to claim 1 or 2, further comprising: i) winding; Ii) seizures; Iii) inflammatory processes; And (iv) fibrosis, and (v) when the treatment or prevention of the disease or disease selected in cancer control is necessary, the cellular activity of the tissue and the cell is controlled for prevention or treatment. 제4항 또는 5항에 있어서, ⅰ) 감기; ⅱ) 발작; ⅲ)염증 과정; ⅳ) 섬유증 그리고 ⅴ) 암 제어에서 선택된 질병 또는 질환의 치료 또는 예방이 필요한 경우에 예방 또는 치료를 위해 조직과 세포의 세포활성을 조절하는 것을 특징으로 하는 용도.The method according to claim 4 or 5, wherein: i) the winding; Ii) seizures; Iii) inflammatory processes; Fibrosis, and v) controlling the cellular activity of tissues and cells for prophylaxis or treatment when treatment or prevention of a disease or disorder selected in cancer control is required. 제17항 또는 8항에 있어서, ⅰ) 감기; ⅱ) 발작; ⅲ)염증 과정; ⅳ) 섬유증 그리고 ⅴ) 암 제어에서 선택된 질병 또는 질환의 치료 또는 예방이 필요한 경우에 예방 또는 치료를 위해 조직과 세포의 세포활성을 조절하는 것을 특징으로 하는 방법.The method according to claim 17 or 8, further comprising: i) winding; Ii) seizures; Iii) inflammatory processes; And (iv) fibrosis, and (v) when the treatment or prevention of the disease or disease selected in cancer control is necessary, the cellular activity of the tissue and the cell is controlled for prevention or treatment. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed by the contents of the first application.
KR1019970701164A 1994-08-30 1995-08-11 HYALURONIC ACID AND DERIVATIVES FOR MODULATION OF CELLULAR ACTIVITY FOR ADJUSTING CELL ACTIVITY Ceased KR970705401A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA002131130A CA2131130A1 (en) 1994-08-30 1994-08-30 Modulation of cellular activity
CA2,131,130 1994-08-30
CA 2145605 CA2145605A1 (en) 1995-03-27 1995-03-27 Modulation of cellular activity
CA2,145,605 1995-03-27
PCT/CA1995/000477 WO1996006622A1 (en) 1991-07-03 1995-08-11 Hyaluronic acid and derivatives for modulation of cellular activity

Publications (1)

Publication Number Publication Date
KR970705401A true KR970705401A (en) 1997-10-09

Family

ID=25677464

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701164A Ceased KR970705401A (en) 1994-08-30 1995-08-11 HYALURONIC ACID AND DERIVATIVES FOR MODULATION OF CELLULAR ACTIVITY FOR ADJUSTING CELL ACTIVITY

Country Status (9)

Country Link
EP (1) EP0778776A1 (en)
JP (1) JPH10504828A (en)
KR (1) KR970705401A (en)
CN (1) CN1130532A (en)
AP (1) AP618A (en)
AU (1) AU3159595A (en)
HU (1) HUT76846A (en)
IL (1) IL114914A0 (en)
WO (1) WO1996006622A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929096T2 (en) 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Human rhinovirus receptor protein that inhibits susceptibility to virus infection
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
CA2268476A1 (en) 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
PL326970A1 (en) * 1995-12-01 1998-11-09 Hyal Pharma Corp Orientation of dosage of drugs and therapeutic agents as well as othe glykozaminoglykanes (gags)
CA2166155C (en) * 1995-12-27 2008-02-05 Eva Anne Turley Agents binding to hyaluronic acid binding domains and the use thereof
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CA2205771C (en) * 1997-05-22 2002-05-14 Hyal Pharmaceutical Corporation Improved delivery of disease modifiers
WO2000038647A1 (en) * 1998-12-23 2000-07-06 Esparma Gmbh Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis
AU773984B2 (en) * 1999-01-13 2004-06-10 Alchemia Oncology Pty Limited A composition and method for the enhancement of the efficacy of drugs
ES2295005T3 (en) * 1999-01-13 2008-04-16 Alchemia Oncology Pty Limited USE OF HIALURONANE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE IMPROVEMENT OF THE EFFECTIVENESS OF CITOTOXIC PHARMACOS.
WO2001080899A2 (en) * 2000-04-20 2001-11-01 Cangene Corporation Rhamm peptide conjugates
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
AU8136801A (en) * 2000-07-31 2002-02-13 Dermal Res Lab Inc Methods of preventing or treating diseases and conditions using complex carbohydrates
WO2003041723A1 (en) * 2001-11-12 2003-05-22 Reinmueller Johannes Pharmaceutical applications of hyaluronic acid preparations
AU2002359404B2 (en) * 2002-11-12 2008-06-05 Omeros Corporation Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation
ES2246694B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. PEGILATED NANOPARTICLES.
ES2246695B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. STIMULATING COMPOSITION OF THE IMMUNE RESPONSE THAT INCLUDES NANOPARTICLES BASED ON A COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE.
US8937052B2 (en) 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EA013877B1 (en) 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
CA2682114C (en) 2007-03-30 2017-08-01 Chu Sainte Justine Method of determining risk of scoliosis
ES2385995B2 (en) 2011-01-10 2013-05-21 Universidade De Santiago De Compostela NANOCAPPSULES WITH POLYMER COVER
US9615750B2 (en) * 2012-06-14 2017-04-11 Seno Medical Instruments, Inc. Methods and compositions for carrier agents and clearing agents used in optoacoustic imaging systems
FR2994846B1 (en) 2012-08-29 2014-12-26 Vivacy Lab COMPOSITION, STERILIZED, COMPRISING AT LEAST ONE HYALURONIC ACID AND MAGNESIUM ASCORBYL PHOSPHATE
FR3020570B1 (en) * 2014-04-30 2017-07-21 Pierre Fabre Dermo Cosmetique ASSOCIATION OF A HYALURONIC ACID AND A SULFATE POLYSACCHARIDE
EP3775713A1 (en) 2018-04-13 2021-02-17 Carrier Corporation Method of defrosting a multiple heat absorption heat exchanger refrigeration system
CA3097470A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for enhancing epithelial survival and reconstitution of body surfaces
CN109481693B (en) * 2018-12-14 2022-02-22 药大制药有限公司 A kind of hyaluronic acid-nonoxynol ether conjugate, preparation method and application
CN118063833B (en) * 2024-04-19 2024-06-28 四川兴泰普乐医疗科技有限公司 Micro-crosslinking sodium hyaluronate gel and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
NO169637C (en) * 1983-10-11 1992-07-22 Fidia Spa PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE HYALURONIC ACID FRACTIONS
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
GB9207949D0 (en) * 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility

Also Published As

Publication number Publication date
IL114914A0 (en) 1995-12-08
AU3159595A (en) 1996-03-22
JPH10504828A (en) 1998-05-12
HUT76846A (en) 1997-12-29
WO1996006622A1 (en) 1996-03-07
EP0778776A1 (en) 1997-06-18
AP618A (en) 1997-10-10
AP9500756A0 (en) 1995-10-31
CN1130532A (en) 1996-09-11

Similar Documents

Publication Publication Date Title
KR970705401A (en) HYALURONIC ACID AND DERIVATIVES FOR MODULATION OF CELLULAR ACTIVITY FOR ADJUSTING CELL ACTIVITY
JP2637682B2 (en) Pharmaceutical composition for treating immunoinflammatory bowel disease
ES2460570T3 (en) Ophthalmic compositions containing a synergistic combination of three polymers
US5614506A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
EP3344256B1 (en) Compositions for the treatment of joints
JPH09512797A (en) Cancer treatment and metastasis prevention
US5674857A (en) Use of hyaluronic acid to repair ischemia reperfusion damage
MXPA02004871A (en) Pharmaceutical combinations.
Sharma et al. Application of Vitamin E TPGS in ocular therapeutics–Attributes beyond excipient
AU641966B2 (en) Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
AU701014B2 (en) Treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction
JP5383695B2 (en) Pharmaceutical composition comprising a bradykinin antagonist and hyaluronic acid and use thereof
AP448A (en) Use of hyaluronic acid and forms to prevent arterial restenosis.
CN101068564B (en) Antitumor composition containing VEGF inhibitor and 5FU or one of its derivatives
JP4210330B2 (en) Hyaluronic acid receptor binding agent and method of use thereof
US5817644A (en) Targeting of dosages of medicine and therapeutic agents
ES2796361T3 (en) Therapeutic use of a sterile aqueous ophthalmic solution
CA2131130A1 (en) Modulation of cellular activity
AU702929B2 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
WO2020128616A2 (en) Methods and compositions for controlling cell migration and proliferation
Khosla et al. Anti-trachoma action and serological profile of Berberine—An Indigenous plant
RU98112263A (en) DIRECTED DELIVERY OF MEDICINES AND THERAPEUTIC AGENTS AND OTHER Glycosaminoglycans (GAGS)
Maitchouk Dexamethasone inserts in the treatment of vernal and giant papillary conjunct IV it is
Chollet et al. Endothelin is mitogenic and haptotaxic for cultured corneal endothelial cells
Maichuk et al. Experimental assessment of topical liposomal cyclosporin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19970224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20000810

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030428

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20030823

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20030428

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I